Frusemide infusion for the prevention of deterioration in renal function post cardiac surgery.

• Conditions: Renal impairment after cardiac surgery.; Surgery - Other surgery; Renal and Urogenital - Other renal and urogenital disorders

• Registration Number: ACTRN12605000386639
• Lead Sponsor: Intensive Care Unit, RMH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion from the pre-admission clinics, and wards of the Cardiothoracic surgery unit. Potential participants will be identified by daily review of planned cardiothoracic surgery schedules. Prior to inclusion in this study permission to approach patients will be obtained from involved treating Intensivists and Surgeons.

Exclusion Criteria

Patients will be excluded if:1.already in established dialysis dependent chronic renal failure.2.known allergy to frusemide. 3.age < 184.Pregnant.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of increase in creatinine of 0.05 mmol/L or greater in the first 72 hours after cardiac surgery[]

Secondary Outcome Measures

Name	Time	Method
1.the maximum change in serum creatinine from baseline value [During the first 7 days of hospital stay ];2.incidence of renal failure requiring any form of renal replacement therapy [];3.Duration of post-operative hospital and ICU stay.[];4.the maximum Sequential Organ Failure Assessment (SOFA) score[In the first 7 days of hospital stay]